

Date: 26th January 2026
Ref: CORP 25/26 - 230

Dear xxx

Freedom of Information request: Blood Cancer Data (CORP 25/26 – 230)

Thank you for your request for information which the Trust received on 6th January 2026.

Your Request:

During the period 1st Jan 2015 to 31st December 2025:

- 1. Annual number of patients diagnosed with blood cancers per year overall, and by subtype:*
 - Lymphomas (C81-86)*
 - Malignant immunoproliferative diseases (C88)*
 - Multiple myeloma and malignant plasma cell neoplasms (C90)*
 - Leukaemia (C91-C95)*
 - Unspecified malignant neoplasms of lymphoid, haematopoietic and related tissues (C96)*
- 2. The number of blood cancer clinical trials available, including active trials that are recruiting and trials that are not actively recruiting.*
- 3. Annual number of patients who were enrolled in interventional or observational clinical trials related to these blood cancers per year.*
- 4. The scientific title, clinical trial registration number, phase (I/II/III/IV/other), opening and closing recruitment dates, number recruited at this trust, and location of each trial related to blood cancer.*
- 5. The current number of dedicated research staff (e.g. research nurses, research practitioners, study coordinators etc.) assigned to haematological clinical trials.*
- 6. If available, annual counts of invitations/offers made to eligible patients to consider trial participation.*


Please find the Trust's response below:

During the period 1st Jan 2015 to 31st December 2025:

- 1. Annual number of patients diagnosed with blood cancers per year overall, and by subtype:**
 - Lymphomas (C81-86)**
 - Malignant immunoproliferative diseases (C88)**
 - Multiple myeloma and malignant plasma cell neoplasms (C90)**
 - Leukaemia (C91-C95)**
 - Unspecified malignant neoplasms of lymphoid, haematopoietic and related tissues (C96)**

Please see Appendix 1 below.

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.



2. The number of blood cancer clinical trials available, including active trials that are recruiting and trials that are not actively recruiting.

Velindre University NHS Trust has no blood cancer clinical trials available within its Research Portfolio that are either:

- Actively recruiting, or
- Open but not actively recruiting.

Velindre University NHS Trust is a tertiary Cancer Centre that primarily treats solid tumour cancers and therefore holds a limited clinical research trials portfolio relating to blood cancers.

3. Annual number of patients who were enrolled in interventional or observational clinical trials related to these blood cancers per year.

Velindre University NHS Trust does not hold aggregated annual enrolment figures for blood cancer clinical trials, as there are no currently active blood cancer trials in the Trust Research Portfolio.

Historic enrolment data for previously open studies is provided at an individual study level in response to Question 4 below.

4. The scientific title, clinical trial registration number, phase (I/II/III/IV/other), opening and closing recruitment dates, number recruited at this trust, and location of each trial related to blood cancer.

While there are no current blood cancer clinical trials, the following studies were previously part of the Velindre University NHS Trust Research Portfolio during the requested period:


i. ZEUS

- o IRAS ID: 242585
- o Full title: Non-interventional study to assess the safety profile of Idelalisib in patients with refractory follicular lymphoma (FL)
- o Phase: Not applicable
- o Site recruitment open date: 30/11/2018
- o Site recruitment close date: 31/03/2021
- o Number recruited at Velindre: 0
- o Notes: Retrospective chart review study with no prospective participant recruitment.

ii. First-in-human dose-escalation study of ATR inhibitor BAY 1895344

- o IRAS ID: 218516
- o Full title: An open-label, first-in-human, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.



dose and/or recommended Phase II dose of the ATR inhibitor BAY 1895344 in patients with advanced solid tumours and lymphomas

- Phase: II
- Site recruitment open date: 02/04/2019
- Site recruitment close date: 02/11/2020
- Number recruited at Velindre: <6* (recruited during FY2019/20)
- Notes: Recruitment paused by the Sponsor during the COVID-19 pandemic and the study did not reopen.

iii. EuroNet-PHL-C2

- IRAS ID: 181571
- Full title: Second International Inter-Group Study for Classical Hodgkin's Lymphoma in Children and Adolescents
- Phase: III
- Site recruitment open date: 27/06/2019
- Site recruitment close date: 31/12/2020
- Number recruited at Velindre: 0
- Notes: Velindre Cancer Centre acted as a non-recruiting radiotherapy site only, providing radiotherapy services.

iv. Cabozantinib in Radioiodine-Refractory Differentiated Thyroid Cancer

- IRAS ID: 259791
- Full title: A Phase III, randomised, double-blind, placebo-controlled study of Cabozantinib (XL184) in subjects with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy
- Phase: III
- Site recruitment open date: 28/08/2019
- Site recruitment close date: 17/03/2021
- Number recruited at Velindre: 0

v. PORT

- IRAS ID: 235979
- Full title: Phase II trial of Pembrolizumab and Radiotherapy in Cutaneous T-cell Lymphoma
- Phase: II
- Site recruitment open date: 30/10/2019
- Site recruitment close date: 21/12/2022
- Number recruited at Velindre: <6* (recruited during FY2021/22)

* Where the figure provided is less than 6, and where simple calculations could identify fields that contain less than 6, the Trust has applied an exemption under Section 40(2) (personal data) of the Freedom of Information Act 2000. This is because the Trust believes there is a potential risk of individuals being able to be identified if the figures were disclosed.

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.

5. The current number of dedicated research staff (e.g. research nurses, research practitioners, study coordinators etc.) assigned to haematological clinical trials.

Velindre University NHS Trust currently has no dedicated research staff (for example, research nurses, research practitioners, or study coordinators) specifically assigned to haematological clinical trials.

Any research activity relating to blood cancer clinical trials has historically been delivered as part of the wider workload of:

- two research nurses, and
- one research facilitation officer.

6. If available, annual counts of invitations/offers made to eligible patients to consider trial participation.

Velindre University NHS Trust does not hold centrally collated data on annual counts of invitations or offers made to eligible patients for blood cancer clinical trial participation. Accordingly, this information is not held for the purposes of this FOI request.

I trust this answers your request for information, however, should you not be satisfied with the information supplied or the process of supplying it, you have a right to complain and request a review. Please note that you must submit a request for a review within 40 days of the date of this letter.


You should forward your complaint to:

Mr Ian Bevan via FOI.VUNHST@wales.nhs.uk
Head of Information Governance
Velindre University NHS Trust
2, Charnwood Court
Heol Billingsley
Parc Nantgarw
Cardiff, CF15 7QZ

Should you wish to take your complaint further, if you are still unhappy with the decision after review, you can contact the:

Information Commissioner's Office - Wales
2nd Floor,
Churchill House,
Churchill Way,
Cardiff, CF10 2HH
Telephone: 0330 414 6421
email: wales@ico.org.uk


Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.



Yours sincerely

Non Gwilym
Interim Director of Corporate Governance
Velindre University NHS Trust
2 Charnwood Court
Heol Billingsley
Parc Nantgarw
Cardiff
CF15 7QZ

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.



APPENDIX 1

Please note: the data shows a count of patients by year of referral, who have been coded with one of the above clinic codes. This is not necessarily the year of diagnosis and does not necessarily encompass all patients in our catchment area who have been diagnosed with one of those cancers. Additionally, not all patients will be clinically coded, VCS only codes all admitted patient care which includes ordinary admissions, day cases and regular day attenders. We do not code outpatient attendances or ward attenders.

Patients may be counted twice where they have been referred more than once to Velindre Cancer Services, or where they have more than one of the queried diagnosis codes

1. Annual number of patients diagnosed with blood cancers per year overall, and by subtype:

- Lymphomas (C81-86)**

2015	C81-C86	78
2016	C81-C86	52
2017	C81-C86	67
2018	C81-C86	66
2019	C81-C86	78
2020	C81-C86	70
2021	C81-C86	63
2022	C81-C86	68
2023	C81-C86	60
2024	C81-C86	49
2025	C81-C86	49
		700

- Malignant immunoproliferative diseases (C88)**

2015	C88	12
2016	C88	7
2017	C88	9
2018	C88	12
2019	C88	12
2020	C88	13
2021	C88	8
2022	C88	12
2023	C88	<6*
2024	C88	6
2025	C88	<6*

- **Multiple myeloma and malignant plasma cell neoplasms (C90)**

2015	C90	17
2016	C90	19
2017	C90	28
2018	C90	26
2019	C90	19
2020	C90	20
2021	C90	34
2022	C90	30
2023	C90	15
2024	C90	19
2025	C90	17
		244

- **Leukaemia (C91-C95)**

2015	C91-C95	29
2016	C91-C95	19
2017	C91-C95	28
2018	C91-C95	25
2019	C91-C95	28
2020	C91-C95	23
2021	C91-C95	23
2022	C91-C95	17
2023	C91-C95	20
2024	C91-C95	14
2025	C91-C95	17
		243

- **Unspecified malignant neoplasms of lymphoid, haematopoietic and related tissues (C96)**

2023	C96	<6*
------	-----	-----

* Where the figure provided is less than 6, and where simple calculations could identify fields that contain less than 6, the Trust has applied an exemption under Section 40(2) (personal data) of the Freedom of Information Act 2000. This is because the Trust believes there is a potential risk of individuals being able to be identified if the figures were disclosed.